Literature DB >> 9579369

Factors affecting survival following local, regional, or distant recurrence from localized melanoma.

S J Soong1, R A Harrison, W H McCarthy, M M Urist, C M Balch.   

Abstract

BACKGROUND AND OBJECTIVES: Approximately one third of all melanoma patients will experience disease recurrence. Factors that affect patient survival following local, regional, or distant first recurrences of localized melanoma are the subject of this investigation.
METHODS: Survival times for a total of 1,085 first recurrences from 4,568 localized melanoma patients were examined in relationship to patient and disease factors by Cox regression. Nearly half (48.8%) of all first recurrences were regional, 21.8% were local, and 29.4% were distant recurrences.
RESULTS: Survival following recurrence differed significantly by site of recurrence (local, regional, or distant; P < 0.0001). Within each site, the median survival time did not differ by time of recurrence following diagnosis. Significant tumor factors for survival following local recurrence included tumor thickness (P = 0.0263) and lesion location (P < 0.0001). For regional recurrences, survival was significantly related to ulceration (P = 0.0105) and whether the recurrence was combined with a local recurrence (P = 0.0429). Survival following distant metastasis was related to number of distant sites (P < 0.0001) and whether a visceral site was involved (P < 0.0001).
CONCLUSIONS: Patient and tumor characteristics predict survival following recurrence. Regardless of disease-free interval, long-term follow-up of melanoma patients is necessary. Patients experiencing distant metastasis have the shortest median survival time compared to patients experiencing local or regional recurrences.

Entities:  

Mesh:

Year:  1998        PMID: 9579369     DOI: 10.1002/(sici)1096-9098(199804)67:4<228::aid-jso4>3.0.co;2-a

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  29 in total

1.  Tumor-infiltrating lymphocytes and mitotic index in metastatic melanoma as predictors of patient survival.

Authors:  Rajmohan Murali; Richard A Scolyer
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-22       Impact factor: 11.205

Review 2.  Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma.

Authors:  Darshil J Shah; Roxana S Dronca
Journal:  Mayo Clin Proc       Date:  2014-04       Impact factor: 7.616

3.  A high proliferative index of recurrent melanoma is associated with worse survival.

Authors:  Ting J Tu; Michelle W Ma; Stefano Monni; Amy E Rose; Herman Yee; Farbod Darvishian; David Polsky; Russell S Berman; Richard L Shapiro; Anna C Pavlick; Madhu Mazumdar; Iman Osman
Journal:  Oncology       Date:  2011-06-24       Impact factor: 2.935

4.  Histopathologic excision margin affects local recurrence rate: analysis of 2681 patients with melanomas < or =2 mm thick.

Authors:  J Gregory McKinnon; Emma C Starritt; Richard A Scolyer; William H McCarthy; John F Thompson
Journal:  Ann Surg       Date:  2005-02       Impact factor: 12.969

5.  The value of FDG PET/CT for follow-up of patients with melanoma: a retrospective analysis.

Authors:  Philip H Vensby; Grethe Schmidt; Andreas Kjær; Barbara M Fischer
Journal:  Am J Nucl Med Mol Imaging       Date:  2017-12-20

6.  Malignant melanoma of the skin: long-term follow-up and time to first recurrence.

Authors:  Annika M Hohnheiser; Olaf Gefeller; Jonas Göhl; Gerold Schuler; Werner Hohenberger; Susanne Merkel
Journal:  World J Surg       Date:  2011-03       Impact factor: 3.352

Review 7.  Long-term follow-up for melanoma patients: is there any evidence of a benefit?

Authors:  Natasha M Rueth; Kate D Cromwell; Janice N Cormier
Journal:  Surg Oncol Clin N Am       Date:  2015-01-24       Impact factor: 3.495

8.  Metabolomic identification of diagnostic serum-based biomarkers for advanced stage melanoma.

Authors:  A W L Bayci; D A Baker; A E Somerset; O Turkoglu; Z Hothem; R E Callahan; R Mandal; B Han; T Bjorndahl; D Wishart; R Bahado-Singh; S F Graham; R Keidan
Journal:  Metabolomics       Date:  2018-08-03       Impact factor: 4.290

9.  Is sentinel lymph node mapping indicated for isolated local and in-transit recurrent melanoma?

Authors:  Katharine A Yao; Eddy C Hsueh; Richard Essner; Leland J Foshag; Leslie A Wanek; Donald L Morton
Journal:  Ann Surg       Date:  2003-11       Impact factor: 12.969

Review 10.  Variability in melanoma post-treatment surveillance practices by country and physician specialty: a systematic review.

Authors:  Kate D Cromwell; Merrick I Ross; Yan Xing; Jeffrey E Gershenwald; Richard E Royal; Anthony Lucci; Jeffrey E Lee; Janice N Cormier
Journal:  Melanoma Res       Date:  2012-10       Impact factor: 3.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.